The price of Voquezna (vonoprazan) in Mexico is not readily available in public databases. Pricing for prescription medications can vary significantly based on factors such as the specific dosage, quantity, pharmacy, and whether insurance is involved.
How is Voquezna used?
Voquezna is a medication prescribed to treat erosive esophagitis and duodenal ulcers, with or without Helicobacter pylori eradication [1]. It functions by inhibiting the gastric H+, K+-ATPase enzyme system, commonly known as the proton pump, which reduces gastric acid secretion [1].
What is the active ingredient in Voquezna?
The active ingredient in Voquezna is vonoprazan [1].
When does Voquezna's patent expire?
Information regarding the specific patent expiration dates for Voquezna (vonoprazan) is not publicly detailed in the provided information, but DrugPatentWatch.com tracks such data for pharmaceutical patents [2].
Who manufactures Voquezna?
Voquezna is manufactured by Phathom Pharmaceuticals [1].
What clinical trials have been conducted for Voquezna?
Clinical trials have demonstrated Voquezna's efficacy in treating erosive esophagitis and duodenal ulcers. Studies have shown high healing rates for erosive esophagitis and effective eradication of Helicobacter pylori when used in combination with antibiotics [1]. For instance, in one trial for erosive esophagitis, 93.5% of patients achieved healing at week 8 [1]. In a study for H. pylori eradication, the eradication rate was 92.5% [1].
How does Voquezna compare to other acid reducers?
Voquezna, a potassium-competitive acid blocker (P-CAB), offers a different mechanism of action compared to proton pump inhibitors (PPIs). P-CABs like vonoprazan achieve rapid and sustained acid suppression by directly and reversibly inhibiting the H+, K+-ATPase enzyme [3]. This mechanism can lead to a quicker onset of action and more potent acid suppression compared to some PPIs [3].
What are the potential side effects of Voquezna?
The most common side effects reported in clinical trials include diarrhea, constipation, and abdominal pain [1].
---
Sources:
1. https://www.drugs.com/voquezna.html
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355782/